JP2022522889A5 - - Google Patents

Info

Publication number
JP2022522889A5
JP2022522889A5 JP2021552586A JP2021552586A JP2022522889A5 JP 2022522889 A5 JP2022522889 A5 JP 2022522889A5 JP 2021552586 A JP2021552586 A JP 2021552586A JP 2021552586 A JP2021552586 A JP 2021552586A JP 2022522889 A5 JP2022522889 A5 JP 2022522889A5
Authority
JP
Japan
Prior art keywords
patient
antibody
stage
composition according
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552586A
Other languages
English (en)
Japanese (ja)
Other versions
JP7619953B2 (ja
JP2022522889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000186 external-priority patent/WO2020178638A1/en
Publication of JP2022522889A publication Critical patent/JP2022522889A/ja
Publication of JP2022522889A5 publication Critical patent/JP2022522889A5/ja
Priority to JP2025003299A priority Critical patent/JP2025063135A/ja
Application granted granted Critical
Publication of JP7619953B2 publication Critical patent/JP7619953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552586A 2019-03-05 2020-03-05 Alアミロイドーシスを処置する方法 Active JP7619953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003299A JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US62/814,252 2019-03-05
US201962942722P 2019-12-02 2019-12-02
US62/942,722 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003299A Division JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Publications (3)

Publication Number Publication Date
JP2022522889A JP2022522889A (ja) 2022-04-20
JP2022522889A5 true JP2022522889A5 (cg-RX-API-DMAC7.html) 2023-03-13
JP7619953B2 JP7619953B2 (ja) 2025-01-22

Family

ID=70476256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552586A Active JP7619953B2 (ja) 2019-03-05 2020-03-05 Alアミロイドーシスを処置する方法
JP2025003299A Pending JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003299A Pending JP2025063135A (ja) 2019-03-05 2025-01-09 Alアミロイドーシスを処置する方法

Country Status (17)

Country Link
US (3) US11692024B2 (cg-RX-API-DMAC7.html)
EP (2) EP3934689B1 (cg-RX-API-DMAC7.html)
JP (2) JP7619953B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220019656A (cg-RX-API-DMAC7.html)
CN (1) CN113811332A (cg-RX-API-DMAC7.html)
AU (1) AU2020231081A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017550A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132780A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002318A1 (cg-RX-API-DMAC7.html)
FR (1) FR3111560B1 (cg-RX-API-DMAC7.html)
IL (1) IL286040A (cg-RX-API-DMAC7.html)
JO (1) JOP20210245A1 (cg-RX-API-DMAC7.html)
MA (1) MA55209A (cg-RX-API-DMAC7.html)
MX (1) MX2021010665A (cg-RX-API-DMAC7.html)
PH (1) PH12021552135A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109645QA (cg-RX-API-DMAC7.html)
WO (1) WO2020178638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55209A (fr) * 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
WO2022056484A1 (en) * 2020-09-14 2022-03-17 Caelum Biosciences Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
KR20240133743A (ko) * 2022-01-11 2024-09-04 프로테나 바이오사이언시즈 리미티드 Al 아밀로이드증 치료 방법
TW202506727A (zh) * 2023-04-10 2025-02-16 美商麥迪紐有限責任公司 優化的cd3抗原結合結構域
TW202547553A (zh) * 2024-02-06 2025-12-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112014009866A2 (pt) * 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CA3129890A1 (en) 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
MA55209A (fr) * 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Similar Documents

Publication Publication Date Title
US20230159647A1 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
JP7164530B2 (ja) Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
MX2007000748A (es) Metodos para tratar el sindrome de sjogren.
US20240141051A1 (en) Methods for treating hand and foot dermatitis by administering an il-4r antagonist
JP2019519584A5 (cg-RX-API-DMAC7.html)
JP2022500382A5 (cg-RX-API-DMAC7.html)
JP2006501283A (ja) LFA−1αサブユニット抗体と利用方法
DE202021004005U1 (de) Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum
JP2024505923A5 (cg-RX-API-DMAC7.html)
US20240350626A1 (en) Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
JP2022520572A5 (cg-RX-API-DMAC7.html)
CN113993543B (zh) 使用抗cd38抗体的组合疗法
US20020110558A1 (en) Use of CD25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
AU2022228198B9 (en) Method for treating multiple sclerosis
US20260070995A1 (en) Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026107143A1 (en) Fixed dose combination of anti-fucosyl-gm1 antibody and anti-pd-1 antibody and uses thereof
KR20260049559A (ko) 이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
Stevenson The prospects for treating cancer with antibody
WO2025106736A2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
HK40022146A (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
HK1216898B (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor